Protocol Ledger

NCT05938920 · Phase II · COMPLETED

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Interventional Phase II clinical trial protocol NCT05938920 sponsored by InSilico Medicine Hong Kong Limited in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-06-19 Enrollment: 71 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05938920
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)71 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05938920
Protocol FieldVerified Registry Value
NCT IdentifierNCT05938920
Consolidated Lead SponsorInSilico Medicine Hong Kong Limited
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment71 participants (ACTUAL)
Registered Start Date2023-06-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI